Journals / ANKEM Dergisi / 2012 / Cilt: 26 - Sayı: 2

Clinical Aspergillus isolates: Evaluation of species distribution and antifungal susceptibility results

Klinik Aspergıllus izolatları: Tür dağılımı ve antifungal duyarlılık sonuçlarının değerlendirilmesi

Pages
69–73
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Consequently, the most common agent of invasive aspergillosis is A. fumigatus and voriconazole may be a reliable alternative to amphotericin B.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although Aspergillus spp. are widespread in the world, invasive Aspergillus infections are important problems for especially immunocompromised patients.
📊
Key Findings & Data:A total of 110 isolates were included and 60 % of them were Aspergillus fumigatus, 21 % Aspergillus niger and 9 % Aspergillus flavus.
💡
Conclusion & Impact:Consequently, the most common agent of invasive aspergillosis is A. fumigatus and voriconazole may be a reliable alternative to amphotericin B.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although Aspergillus spp. are widespread in the world, invasive Aspergillus infections are important problems for especially immunocompromised patients. In this study, the species distribution and antifungal susceptibility test results of Aspergillus spp. isolated in our hospital were analyzed. A total of 110 isolates were included and 60 % of them were Aspergillus fumigatus, 21 % Aspergillus niger and 9 % Aspergillus flavus. Of the isolates, 54 % were obtained from the patients of Department of Chest Diseases and 75 % were isolated from respiratory tract specimens. E-test method was performed for antifungal susceptibility testing and minimal inhibitory concentration ranges were found as 0.012-32 μg/ml for amphotericin B, 0.008-128 μg/ml for itraconazole and 0.023-8 μg/ml for voriconazole. The most potent agent was voriconazole among three antifungals tested. Consequently, the most common agent of invasive aspergillosis is A. fumigatus and voriconazole may be a reliable alternative to amphotericin B.

Özet

Aspergillus türleri tüm dünyada yaygın olarak bulunmakla birlikte, özellikle immündüşkün hastalar için invazif Aspergillus infeksiyonları önemli bir problemdir. Bu çalışmada, hastanemizde izole edilmiş Aspergillus izolatlarının tür dağılımı ve antifungal duyarlılığı analiz edilmiştir. Toplam 110 izolat analize alınmış ve bunların % 60’ı Aspergillus fumigatus, % 21’i Aspergillus niger, % 9’u ise Aspergillus flavus olarak tanımlanmıştır. İzolatların % 54’ü Göğüs Hastalıkları Servisi hastalarından ve % 75’i solunum yolu örneklerinden elde edilmiştir. Antifungal duyarlılık testi için E-test yöntemi kullanılmış ve minimal inhibitör konsantrasyon aralıkları amfoterisin B için 0.012-32 μg/ml, itrakonazol için 0.008-128 μg/ml ve vorikonazol için 0.023-8 μg/ml olarak bulunmuştur. Test edilen üç antifungal arasında en etkilisi vorikonazol olmuştur. Sonuç olarak invazif aspergillozların en sık etkeni A.fumigatus’tur ve vorikonazol amfoterisin B’ye güvenilir bir alternatif olabilir.

🔖

Cite This Article

ÖZ, Y., AKŞİT, F., ASLAN, M., KAŞİFOĞLU, N., KİRAZ, N. (2012). Clinical Aspergillus isolates: Evaluation of species distribution and antifungal susceptibility results. ANKEM Dergisi, Cilt: 26 - Sayı: 2, 69–73. https://ajindex.com/articles/156754

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Aneja KR, Sharma C, Joshi R. Fungal infection of the ear: a common problem in the northeastern part of Haryana, Int J Pediatr Otorhinolaryngol 2010
  2. 74(6):604-7. http://dx.doi.org/10.1016/j.ijporl.2010.03.001 PMid:20347163 2. Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy study, Eur J Clin Microbiol Infect Dis 1992
  3. 11(2):99-109. PubMedPMID:1396746 3. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds, Antimicrob Agents Chemother 2009
  4. 53(5):2192-5. http://dx.doi.org/10.1128/AAC.01543-08 PMid:19223630 PMCid:2681500 4. Değerli K, Akçalı S, Sezgin C, Ünlü H, Özbak-kaloğlu B. Manisa ve çevresinde soyutlanan otomikoz etkenleri, İnfeksiyon Derg 2002
  5. 16(2):211-3. http://infeksiyon.dergisi.org/text.php3?id=179 5. Jia X, Liang Q, Chi F, Cao W. Otomycosis in Shanghai: aetiology, clinical features and therapy, Mycoses 2011
  6. doi: 10.1111/j.1439-507.2011.02132.x. PubMed PMID: 21999222 6. Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance, Mycoses 2009
  7. 52(3):206-22. http://dx.doi.org/10.1111/j.1439-0507.2008.01642.x PMid:19207851 7. Lass-Flörl C, Perkhofer S. In vitro susceptibility-testing in Aspergillus species, Mycoses 2008
  8. 51(5):437-46. http://dx.doi.org/10.1111/j.1439-0507.2008.01510.x PMid:18422914 8. Ozcan KM, Ozcan M, Karaarslan A Karaarslan F. Otomycosis in Turkey: predisposing factors, aetiology and therapy, J Laryngol Otol 2003
  9. 117(1):39-42. PubMed PMID: 12590854 http://dx.doi.org/10.1258/002221503321046621 9. Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000, Antimicrob Agents Chemother 2002
  10. 46(4):1032-7. http://dx.doi.org/10.1128/AAC.46.4.1032-1037.2002 PMid:11897586 PMCid:127116 10. Pfaller MA, Messer SA, Mills K, Bolmström A. In vitro susceptibility testing of filamentous fungi: comparison of E test and reference microdilution methods for determining itraconazole MICs, J Clin Microbiol 2000
  11. 38(9):3359-61. PubMedPMID: 10970383
  12. PubMed Central PMCID: PMC87386. 11. Rolston K. Overview of syst